The effects of levetiracetam on cognition: A non-interventional surveillance study

Objective and subjective cognitive measures were evaluated in 401 patients before and 3 and 6 months after introducing levetiracetam (LEV). Initially, cognitive impairment was indicated in 37-44% of the patients, and subjective impairments in 32-67%. With LEV, 87% of untreated patients changed to monotherapy, and 94% changed from mono- to polytherapy. The rate of retention of LEV was 97%; adverse events were reported by 7%. Under LEV, 36% achieved early seizure control, 25% achieved late seizure control, 33% continued to have seizures, and 7% had a relapse. Very good tolerance was reported by 68%, and cognitive improvement by 58%. Objective improvement was significant in 23-29% of the patients; 5-6% deteriorated. Better baseline scores, later-onset epilepsies, fewer initial antiepileptic drugs, and seizure control were predictive of a better cognitive outcome. Considering the uncontrolled study design and the increase in total drug load, LEV appeared safe and efficacious, and a general subjective and objective cognitive improvement could be noted. However, a controlled study design would be required to attribute these improvements to a specific drug action.

[1]  A. Aldenkamp,et al.  Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  J. Cramer,et al.  A systematic review of the safety profile of levetiracetam: a new antiepileptic drug , 2001, Epilepsy Research.

[3]  S. Berkovic,et al.  Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study , 2005, Epilepsy Research.

[4]  P. Smith,et al.  Levetiracetam as add-on therapy in generalised epilepsies , 2004, Seizure.

[5]  Neri Accornero,et al.  Clinical, Cognitive, and Neurophysiologic Correlates of Short-Term Treatment with Carbamazepine, Oxcarbazepine, and Levetiracetam in Healthy Volunteers , 2004, The Annals of pharmacotherapy.

[6]  A. Schulze-Bonhage,et al.  Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy , 2006, Seizure.

[7]  A. Aldenkamp,et al.  Newer Antiepileptic Drugs and Cognitive Issues , 2003, Epilepsia.

[8]  Dong Zhou,et al.  Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures , 2008, Epilepsy & Behavior.

[9]  Simon Shorvon,et al.  Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures , 2000 .

[10]  C. Helmstaedter,et al.  EpiTrack: Tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy , 2005, Epilepsy & Behavior.

[11]  R. Leroy,et al.  Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy , 2007, Neurology.

[12]  K. Meador,et al.  The relationship between memory performance, perceived cognitive function, and mood in patients with epilepsy , 1999, Epilepsy Research.

[13]  G. Bergey.  Evidence‐based Treatment of Idiopathic Generalized Epilepsies with New Antiepileptic Drugs , 2005, Epilepsia.

[14]  Ho-Won Lee,et al.  Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients , 2008, Epilepsy & Behavior.

[15]  K. Meador,et al.  Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam , 2007, Neurology.

[16]  K. Meador,et al.  Cognitive side effects of antiepileptic drugs , 2004, Epilepsy & Behavior.

[17]  Raffaele Canger,et al.  Levetiracetam: An improvement of attention and of oral fluency in patients with partial epilepsy , 2006, Epilepsy Research.

[18]  J. Cramer,et al.  Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam , 2003, Epilepsy & Behavior.

[19]  K. Meador.  Cognitive and memory effects of the new antiepileptic drugs , 2006, Epilepsy Research.

[20]  Bernhard J. Steinhoff,et al.  Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: A comparative short-term study , 2006, Epilepsy & Behavior.

[21]  Christian E Elger,et al.  Long‐term memory impairment in patients with focal epilepsy , 2007, Epilepsia.

[22]  A. Schulze-Bonhage,et al.  The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate , 2007, Epilepsy & Behavior.

[23]  R. Kuzniecky,et al.  Subjective versus objective memory change after temporal lobe epilepsy surgery. , 1999, Neurology.